Hospital
Carolinas Medical Center
Carolinas Medical Center was paid $177.75M by Medicaid between Jan 2018 and Dec 2024, across 441 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoCAROLINAS MEDICAL CENTER
CHARLOTTE, NC 28203
CHARLOTTE, NC 28203
33aNPI1295789907assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$177.75M
24GClaims3,108,568
24DCodes billed441
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#1 of 92
Median peer was paid$11.47M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 406,855 | $16.16M | |
| 2019 | 396,297 | $18.32M | |
| 2020 | 323,928 | $15.57M | |
| 2021 | 492,416 | $30.25M | |
| 2022 | 467,241 | $32.55M | |
| 2023 | 518,019 | $33.40M | |
| 2024incomplete | 503,812 | $31.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 97,300 | 91,048 | $39.48M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 73,525 | 68,075 | $28.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 8.1% | 538,951 | 466,835 | $14.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 27,300 | 24,975 | $8.13M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 78,509 | 69,340 | $7.18M |
| J3490 | Unclassified drugs | 4.0% | 130,700 | 63,476 | $7.11M |
| 80053 | Comprehensive metabolic panel | 2.8% | 133,421 | 113,726 | $5.05M |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 2.7% | 8,522 | 3,968 | $4.81M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 3,662 | 2,144 | $4.15M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.0% | 115,011 | 103,035 | $3.52M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 114,059 | 102,105 | $2.92M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 7,994 | 4,469 | $2.47M |
429 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 15,488 | $2.41M |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 73,058 | $2.10M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 15,533 | $1.66M |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,531 | $1.47M |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 55,219 | $1.30M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,630 | $1.27M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 47,997 | $1.26M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 52,050 | $1.20M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,714 | $1.19M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 145,465 | $1.12M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,943 | $1.01M |
| G0378 | Hospital observation service, per hour | <1% | 8,288 | $950K |
| 36591 | <1% | 2,732 | $936K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 27,731 | $852K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,496 | $817K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 174 | $785K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,799 | $746K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 47,807 | $743K |
| 87070 | <1% | 46,220 | $732K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,148 | $692K |
| 59025 | Fetal non-stress test | <1% | 5,238 | $670K |
| 36512 | <1% | 1,412 | $669K | |
| 80061 | Lipid panel | <1% | 36,998 | $668K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 42,859 | $631K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,347 | $620K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,658 | $599K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,857 | $574K |
| 86592 | <1% | 53,214 | $569K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,472 | $528K |
| Q3014 | Telehealth originating site facility fee | <1% | 22,507 | $519K |
| 99199 | Unlisted special service, procedure or report | <1% | 52,574 | $505K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,716 | $497K |
| 83020 | <1% | 11,743 | $484K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,722 | $481K |
| 64643 | <1% | 1,729 | $471K | |
| 96367 | <1% | 416 | $469K | |
| 64642 | <1% | 2,340 | $466K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,479 | $456K |
| 85027 | <1% | 57,011 | $404K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,983 | $393K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 5,988 | $382K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24,667 | $378K |
| 87081 | <1% | 30,809 | $374K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,763 | $364K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32,482 | $344K |
| 82962 | <1% | 11,477 | $336K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 15,582 | $336K |
| S0028 | Injection, famotidine, 20 mg | <1% | 550 | $328K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,155 | $315K |
| 80069 | <1% | 8,711 | $309K | |
| 82728 | <1% | 18,726 | $307K | |
| 54161 | <1% | 326 | $298K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,366 | $296K |
| 84439 | <1% | 24,794 | $285K | |
| 81025 | <1% | 19,520 | $272K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 951 | $269K |
| 86923 | <1% | 880 | $245K | |
| 95700 | <1% | 196 | $241K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 5,160 | $237K |
| 86850 | <1% | 18,727 | $234K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,614 | $227K |
| 87486 | <1% | 2,735 | $224K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,047 | $220K |
| 95714 | <1% | 173 | $215K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,212 | $211K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 3,330 | $210K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,377 | $201K |
| 81003 | <1% | 24,757 | $197K | |
| 86360 | <1% | 3,734 | $195K | |
| 86803 | <1% | 12,947 | $181K | |
| 94010 | <1% | 1,733 | $170K | |
| 87480 | <1% | 5,157 | $165K | |
| 86359 | <1% | 3,732 | $157K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,661 | $152K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,472 | $149K |
| 87340 | <1% | 18,045 | $143K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,959 | $143K |
| 99177 | <1% | 2,411 | $142K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,642 | $142K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,868 | $141K |
| 87536 | <1% | 3,874 | $141K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 6,917 | $137K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 1,493 | $136K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,721 | $131K |
| 86920 | <1% | 315 | $128K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,195 | $123K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,740 | $122K |
| 0001A | <1% | 2,494 | $120K | |
| 0002A | <1% | 2,306 | $120K | |
| 83021 | <1% | 2,051 | $120K | |
| 82950 | <1% | 6,794 | $118K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 243 | $117K |
| 87660 | <1% | 5,176 | $117K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 193 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,090 | $113K |
| 86762 | <1% | 9,659 | $110K | |
| 87510 | <1% | 5,169 | $99K | |
| 82570 | <1% | 4,368 | $95K | |
| 82607 | <1% | 6,816 | $94K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,077 | $92K |
| 76801 | <1% | 972 | $88K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 573 | $85K |
| 86787 | <1% | 5,753 | $83K | |
| 87581 | <1% | 2,735 | $79K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 808 | $79K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 182 | $77K |
| 90999 | Dialysis (unlisted procedure) | <1% | 910 | $76K |
| 86140 | <1% | 11,325 | $75K | |
| 91200 | <1% | 357 | $73K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 393 | $73K |
| 84484 | <1% | 8,543 | $71K | |
| 80076 | <1% | 2,545 | $70K | |
| 80047 | <1% | 3,115 | $69K | |
| 81001 | <1% | 16,358 | $69K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,943 | $68K |
| 36430 | <1% | 430 | $68K | |
| 54300 | <1% | 98 | $68K | |
| 86780 | <1% | 3,091 | $64K | |
| 76770 | <1% | 324 | $62K | |
| 85045 | <1% | 14,878 | $60K | |
| A9270 | Non-covered item or service | <1% | 5,956 | $59K |
| 84702 | <1% | 3,286 | $55K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,132 | $55K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,063 | $52K |
| 82330 | <1% | 2,349 | $51K | |
| 82105 | <1% | 2,298 | $51K | |
| 36593 | <1% | 769 | $50K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 78 | $50K |
| 85007 | <1% | 3,776 | $49K | |
| 95951 | <1% | 60 | $48K | |
| 90677 | <1% | 922 | $48K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 85 | $46K |
| 87077 | <1% | 2,199 | $46K | |
| 82784 | <1% | 3,549 | $45K | |
| 83690 | <1% | 8,878 | $45K | |
| 43762 | <1% | 290 | $43K | |
| 84466 | <1% | 7,033 | $43K | |
| 86900 | <1% | 15,819 | $40K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 485 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,564 | $39K |
| 11045 | <1% | 92 | $39K | |
| 74018 | <1% | 768 | $38K | |
| 86901 | <1% | 15,912 | $37K | |
| 14040 | <1% | 68 | $36K | |
| 81002 | <1% | 9,396 | $35K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 480 | $33K |
| 82565 | <1% | 1,447 | $33K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,683 | $32K |
| 90715 | <1% | 2,193 | $32K | |
| 83540 | <1% | 7,791 | $31K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 17 | $30K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,902 | $30K |
| 83615 | <1% | 7,046 | $30K | |
| 87535 | <1% | 876 | $29K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,196 | $29K |
| 0031A | <1% | 607 | $29K | |
| 90837 | Psychotherapy session, about an hour | <1% | 2,162 | $28K |
| 96409 | <1% | 244 | $28K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,949 | $27K |
| 90686 | <1% | 18,907 | $27K | |
| 97597 | <1% | 924 | $26K | |
| 80050 | General health panel | <1% | 825 | $26K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,144 | $26K |
| 76820 | <1% | 346 | $25K | |
| 80197 | <1% | 3,023 | $25K | |
| 20610 | <1% | 215 | $24K | |
| 83735 | <1% | 10,472 | $24K | |
| 85610 | <1% | 9,117 | $23K | |
| J2323 | Injection, natalizumab, 1 mg | <1% | 12 | $22K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 699 | $21K |
| 97803 | <1% | 2,060 | $21K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 104 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 831 | $21K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 298 | $20K |
| 97802 | <1% | 691 | $19K | |
| 49591 | <1% | 12 | $19K | |
| 83880 | <1% | 1,517 | $18K | |
| 0012A | <1% | 378 | $17K | |
| 85018 | <1% | 4,962 | $16K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,554 | $15K |
| 86003 | <1% | 109 | $15K | |
| 82610 | <1% | 987 | $15K | |
| 83970 | <1% | 957 | $15K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,766 | $15K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 102 | $15K |
| 86902 | <1% | 2,429 | $15K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 156 | $14K |
| 86480 | <1% | 309 | $14K | |
| 88342 | <1% | 146 | $14K | |
| 90678 | <1% | 112 | $14K | |
| 85660 | <1% | 2,467 | $14K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 187 | $14K |
| 82977 | <1% | 2,321 | $13K | |
| 87538 | <1% | 372 | $13K | |
| 0011A | <1% | 413 | $13K | |
| 82803 | <1% | 676 | $12K | |
| 87147 | <1% | 4,049 | $12K | |
| 83516 | <1% | 1,007 | $12K | |
| 82248 | <1% | 2,242 | $11K | |
| 96127 | <1% | 1,920 | $11K | |
| 85652 | <1% | 5,923 | $11K | |
| 0071A | <1% | 199 | $11K | |
| 86038 | <1% | 826 | $11K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 541 | $10K |
| 82746 | <1% | 1,374 | $10K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 85 | $10K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 241 | $10K |
| 82550 | <1% | 767 | $10K | |
| 82043 | <1% | 1,303 | $10K | |
| 87205 | <1% | 2,604 | $10K | |
| 87186 | <1% | 3,531 | $10K | |
| 90656 | <1% | 721 | $9K | |
| 84146 | <1% | 341 | $9K | |
| C1769 | Guide wire | <1% | 211 | $9K |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | <1% | 29 | $9K |
| 87210 | <1% | 1,979 | $8K | |
| 83605 | <1% | 2,163 | $8K | |
| 84100 | <1% | 3,261 | $8K | |
| 84450 | <1% | 2,241 | $8K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,082 | $8K |
| 83655 | <1% | 476 | $8K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 499 | $7K |
| 82670 | <1% | 163 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 441 | $7K |
| 82150 | <1% | 647 | $7K | |
| 80074 | <1% | 96 | $7K | |
| 0072A | <1% | 112 | $7K | |
| 64483 | <1% | 21 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 230 | $6K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 81 | $6K |
| 84305 | <1% | 366 | $6K | |
| 0124A | <1% | 145 | $6K | |
| 0004A | <1% | 114 | $6K | |
| 82075 | <1% | 851 | $6K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 41 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 449 | $5K |
| 84153 | <1% | 547 | $5K | |
| 83001 | <1% | 348 | $5K | |
| 96380 | <1% | 350 | $4K | |
| 87040 | <1% | 733 | $4K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 32 | $4K |
| 87430 | <1% | 230 | $4K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 100 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 68 | $4K |
| 84460 | <1% | 2,351 | $4K | |
| 94060 | <1% | 15 | $4K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 43 | $3K |
| 82951 | <1% | 216 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 52 | $3K |
| 11982 | <1% | 12 | $3K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 13 | $3K |
| 84156 | <1% | 2,261 | $3K | |
| 86364 | <1% | 819 | $3K | |
| 93299 | <1% | 253 | $3K | |
| 93886 | <1% | 12 | $3K | |
| 87799 | <1% | 521 | $3K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 73 | $3K |
| 82103 | <1% | 142 | $3K | |
| 82104 | <1% | 127 | $3K | |
| 80055 | <1% | 121 | $3K | |
| 90620 | <1% | 75 | $3K | |
| 96415 | <1% | 338 | $2K | |
| 84403 | <1% | 254 | $2K | |
| 86160 | <1% | 72 | $2K | |
| 82677 | <1% | 117 | $2K | |
| 82947 | <1% | 415 | $2K | |
| 80081 | <1% | 16 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 69 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 34 | $2K |
| 87641 | <1% | 53 | $2K | |
| 0052A | <1% | 35 | $2K | |
| 83993 | <1% | 68 | $2K | |
| 85014 | <1% | 2,265 | $2K | |
| 51798 | <1% | 174 | $2K | |
| 84154 | <1% | 155 | $2K | |
| 97167 | <1% | 14 | $2K | |
| 0054A | <1% | 29 | $2K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 14 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $2K |
| 74230 | <1% | 12 | $2K | |
| 86336 | <1% | 117 | $2K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 82 | $2K |
| 86258 | <1% | 36 | $1K | |
| 96376 | <1% | 1,078 | $1K | |
| 86334 | <1% | 97 | $1K | |
| 87808 | <1% | 136 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 68 | $1K |
| 83521 | <1% | 115 | $1K | |
| 0352U | <1% | 34 | $1K | |
| 58301 | <1% | 13 | $1K | |
| 86317 | <1% | 39 | $1K | |
| 90480 | <1% | 63 | $1K | |
| 86231 | <1% | 36 | $1K | |
| 73552 | <1% | 28 | $1K | |
| 86704 | <1% | 100 | $1K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 383 | $1K |
| 86376 | <1% | 65 | $1K | |
| 91322 | <1% | 45 | $1K | |
| 99381 | <1% | 36 | $999.73 | |
| 58300 | <1% | 13 | $998.09 | |
| 92611 | <1% | 13 | $949.16 | |
| 82390 | <1% | 57 | $926.30 | |
| 84165 | <1% | 141 | $908.10 | |
| 84481 | <1% | 65 | $899.31 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 29 | $895.88 |
| 96156 | <1% | 15 | $881.20 | |
| 64415 | <1% | 13 | $862.34 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 164 | $857.34 |
| 11981 | <1% | 14 | $852.39 | |
| 83550 | <1% | 227 | $806.94 | |
| 84425 | <1% | 27 | $800.12 | |
| 72081 | <1% | 16 | $799.87 | |
| 85730 | <1% | 929 | $774.81 | |
| 97161 | <1% | 17 | $771.30 | |
| 86696 | <1% | 47 | $757.28 | |
| 83520 | <1% | 53 | $743.65 | |
| 87088 | <1% | 1,132 | $740.52 | |
| 85240 | <1% | 29 | $736.23 | |
| 87497 | <1% | 318 | $718.72 | |
| 93297 | <1% | 99 | $703.57 | |
| 85347 | <1% | 69 | $697.64 | |
| 83002 | <1% | 44 | $692.73 | |
| 82533 | <1% | 28 | $668.67 | |
| 72170 | <1% | 13 | $656.89 | |
| 88184 | <1% | 13 | $648.42 | |
| 83718 | <1% | 47 | $622.38 | |
| 73630 | <1% | 14 | $610.09 | |
| 82627 | <1% | 15 | $597.99 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 12 | $584.13 |
| 76942 | <1% | 13 | $570.60 | |
| 84163 | <1% | 67 | $567.15 | |
| 86706 | <1% | 220 | $557.49 | |
| 86769 | <1% | 16 | $551.47 | |
| 86225 | <1% | 27 | $549.18 | |
| 87276 | <1% | 39 | $542.64 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 14 | $519.22 |
| 87275 | <1% | 37 | $514.08 | |
| 82952 | <1% | 123 | $509.92 | |
| 84590 | <1% | 25 | $482.25 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 139 | $463.42 |
| 84478 | <1% | 47 | $436.89 | |
| J0612 | Injection, calcium gluconate, not otherwise specified, 10 mg | <1% | 30 | $431.47 |
| 82465 | <1% | 77 | $430.57 | |
| 86664 | <1% | 39 | $428.65 | |
| 83631 | <1% | 15 | $426.08 | |
| 86695 | <1% | 31 | $419.04 | |
| C1780 | Lens, intraocular (new technology) | <1% | 14 | $418.59 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 165 | $413.48 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 145 | $413.39 |
| 86431 | <1% | 106 | $395.72 | |
| 84550 | <1% | 388 | $380.57 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 419 | $373.86 |
| 94761 | <1% | 62 | $373.03 | |
| 84446 | <1% | 13 | $328.63 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 152 | $324.48 |
| 84402 | <1% | 15 | $317.20 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 92 | $297.33 |
| 82397 | <1% | 13 | $295.47 | |
| 87206 | <1% | 109 | $237.12 | |
| 96161 | <1% | 144 | $233.82 | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 16 | $230.80 |
| 82525 | <1% | 12 | $228.54 | |
| 84630 | <1% | 12 | $209.76 | |
| 86702 | <1% | 16 | $208.89 | |
| 82247 | <1% | 34 | $195.34 | |
| 86255 | <1% | 37 | $195.13 | |
| 82378 | <1% | 17 | $189.12 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 69 | $187.59 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 93 | $175.28 |
| 88307 | <1% | 12 | $168.75 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 320 | $168.70 |
| 86701 | <1% | 16 | $157.73 | |
| 86663 | <1% | 26 | $147.06 | |
| 87046 | <1% | 13 | $141.00 | |
| 87045 | <1% | 13 | $141.00 | |
| 84480 | <1% | 15 | $140.56 | |
| A6456 | Zinc paste impregnated bandage, non-elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 34 | $138.53 |
| 83883 | <1% | 57 | $135.52 | |
| 88304 | <1% | 13 | $132.42 | |
| 82985 | <1% | 14 | $131.93 | |
| 81015 | <1% | 14 | $126.26 | |
| 90732 | <1% | 12 | $122.30 | |
| 86015 | <1% | 13 | $96.97 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 28 | $83.08 |
| 86593 | <1% | 15 | $82.58 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 69 | $82.48 |
| 82140 | <1% | 15 | $72.88 | |
| G0008 | Administration of influenza virus vaccine | <1% | 242 | $68.87 |
| 82272 | <1% | 14 | $66.25 | |
| 82042 | <1% | 15 | $48.98 | |
| 82270 | <1% | 13 | $48.60 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 18 | $47.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $39.88 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 45 | $35.59 |
| 96160 | <1% | 14 | $30.85 | |
| 82805 | <1% | 16 | $24.00 | |
| 91307 | <1% | 177 | $15.35 | |
| 83068 | <1% | 29 | $14.90 | |
| 90662 | <1% | 46 | $14.58 | |
| 99173 | <1% | 71 | $12.55 | |
| 92551 | <1% | 62 | $11.50 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 91 | $0.00 |
| 91301 | 0% | 790 | $0.00 | |
| 90680 | 0% | 13 | $0.00 | |
| 90474 | 0% | 13 | $0.00 | |
| 90723 | 0% | 33 | $0.00 | |
| 90647 | 0% | 24 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 26 | $0.00 |
| 91303 | 0% | 586 | $0.00 | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 40 | $0.00 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 26 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 14 | $0.00 |
| 86705 | 0% | 14 | $0.00 | |
| 91300 | 0% | 3,687 | $0.00 | |
| 76937 | 0% | 40 | $0.00 | |
| G0479 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service | 0% | 20 | $0.00 |
| 81329 | 0% | 54 | $0.00 | |
| A0425 | Ground mileage, per statute mile | 0% | 147 | $0.00 |
| 90648 | 0% | 17 | $0.00 | |
| 90685 | 0% | 15 | $0.00 | |
| 91312 | 0% | 150 | $0.00 | |
| 90670 | 0% | 76 | $0.00 | |
| 86665 | 0% | 13 | $0.00 | |
| 86008 | 0% | 12 | $0.00 | |
| 90750 | 0% | 14 | $0.00 | |
| 96417 | 0% | 20 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| 90710 | 0% | 15 | $0.00 | |
| 93975 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.